caa a22 4500 605503788 CHVBK 20210128100612.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s00253-014-6318-y doi (NATIONALLICENCE)springer-10.1007/s00253-014-6318-y Sustainable source of omega-3 eicosapentaenoic acid from metabolically engineered Yarrowia lipolytica [Elektronische Daten] from fundamental research to commercial production [Dongming Xie, Ethel Jackson, Quinn Zhu] The omega-3 fatty acids, cis-5, 8, 11, 14, and 17-eicosapentaenoic acid (C20:5; EPA) and cis-4, 7, 10, 13, 16, and 19-docosahexaenoic acid (C22:6; DHA), have wide-ranging benefits in improving heart health, immune function, mental health, and infant cognitive development. Currently, the major source for EPA and DHA is from fish oil, and a minor source of DHA is from microalgae. With the increased demand for EPA and DHA, DuPont has developed a clean and sustainable source of the omega-3 fatty acid EPA through fermentation using metabolically engineered strains of Yarrowia lipolytica. In this mini-review, we will focus on DuPont's technology for EPA production. Specifically, EPA biosynthetic and supporting pathways have been introduced into the oleaginous yeast to synthesize and accumulate EPA under fermentation conditions. This Yarrowia platform can also produce tailored omega-3 (EPA, DHA) and/or omega-6 (ARA, GLA) fatty acid mixtures in the cellular lipid profiles. Fundamental research such as metabolic engineering for strain construction, high-throughput screening for strain selection, fermentation process development, and process scale-up were all needed to achieve the high levels of EPA titer, rate, and yield required for commercial application. Here, we summarize how we have combined the fundamental bioscience and the industrial engineering skills to achieve large-scale production of Yarrowia biomass containing high amounts of EPA, which led to two commercial products, New Harvest™ EPA oil and Verlasso® salmon. The Author(s), 2015 Yarrowia lipolytica nationallicence Omega-3 fatty acid nationallicence Metabolic engineering nationallicence Fermentation nationallicence Commercialization nationallicence Xie Dongming Biotechnology, Central Research and Development, E.I. du Pont de Nemours and Company, Wilmington, DE, USA aut Jackson Ethel Biotechnology, Central Research and Development, E.I. du Pont de Nemours and Company, Wilmington, DE, USA aut Zhu Quinn Biotechnology, Central Research and Development, E.I. du Pont de Nemours and Company, Wilmington, DE, USA aut Applied Microbiology and Biotechnology Springer Berlin Heidelberg 99/4(2015-02-01), 1599-1610 0175-7598 99:4<1599 2015 99 253 https://doi.org/10.1007/s00253-014-6318-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00253-014-6318-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Xie Dongming Biotechnology, Central Research and Development, E.I. du Pont de Nemours and Company, Wilmington, DE, USA aut NATIONALLICENCE 700 1- Jackson Ethel Biotechnology, Central Research and Development, E.I. du Pont de Nemours and Company, Wilmington, DE, USA aut NATIONALLICENCE 700 1- Zhu Quinn Biotechnology, Central Research and Development, E.I. du Pont de Nemours and Company, Wilmington, DE, USA aut NATIONALLICENCE 773 0- Applied Microbiology and Biotechnology Springer Berlin Heidelberg 99/4(2015-02-01), 1599-1610 0175-7598 99:4<1599 2015 99 253